{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:14:51Z","timestamp":1769598891693,"version":"3.49.0"},"publisher-location":"Cham","reference-count":26,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030630607","type":"print"},{"value":"9783030630614","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-63061-4_25","type":"book-chapter","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T20:34:36Z","timestamp":1607546076000},"page":"285-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In Silico Evaluation of Daclizumab and Vitamin D Effects in Multiple Sclerosis Using Agent Based Models"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0231-7653","authenticated-orcid":false,"given":"Marzio","family":"Pennisi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6616-7856","authenticated-orcid":false,"given":"Giulia","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5062-4696","authenticated-orcid":false,"given":"Giuseppe","family":"Sgroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4646-9851","authenticated-orcid":false,"given":"Giuseppe Alessandro Parasiliti","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-3320","authenticated-orcid":false,"given":"Francesco","family":"Pappalardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"issue":"24","key":"25_CR1","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1001\/jama.286.24.3083","volume":"286","author":"A Ascherio","year":"2001","unstructured":"Ascherio, A., et al.: Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286(24), 3083\u20133088 (2001)","journal-title":"JAMA"},{"issue":"5","key":"25_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1084\/jem.20011629","volume":"195","author":"F Barrat","year":"2002","unstructured":"Barrat, F., et al.: In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195(5), 603\u2013613 (2002)","journal-title":"J. Exp. Med."},{"key":"25_CR3","series-title":"Lecture Notes in Computer Science","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/978-3-030-10549-5_49","volume-title":"Euro-Par 2018: Parallel Processing Workshops","author":"M Beccuti","year":"2019","unstructured":"Beccuti, M., et al.: GPU accelerated analysis of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis. In: Mencagli, G., et al. (eds.) Euro-Par 2018. LNCS, vol. 11339, pp. 626\u2013637. Springer, Cham (2019). https:\/\/doi.org\/10.1007\/978-3-030-10549-5_49"},{"issue":"4","key":"25_CR4","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.4049\/jimmunol.133.4.1748","volume":"133","author":"A Bhalla","year":"1984","unstructured":"Bhalla, A., Amento, E., Glimcher, B.S.L.: 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J. Immunol. 133(4), 1748\u20131754 (1984)","journal-title":"J. Immunol."},{"issue":"Suppl 1","key":"25_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1212\/WNL.0b013e3181c97ed3","volume":"74","author":"B Bielekova","year":"2010","unstructured":"Bielekova, B., Becker, B.L.: Monoclonal antibodies in MS: mechanisms of action. Neurology 74(Suppl 1), 31\u201340 (2010)","journal-title":"Neurology"},{"issue":"15","key":"25_CR6","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.1073\/pnas.0601335103","volume":"103","author":"B Bielekova","year":"2006","unstructured":"Bielekova, B., et al.: Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2R$$\\alpha $$-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA 103(15), 5941\u20135946 (2006)","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"21","key":"25_CR7","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1212\/WNL.0b013e318239f7ef","volume":"77","author":"B Bielekova","year":"2011","unstructured":"Bielekova, B., et al.: Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 77(21), 1877\u20131886 (2011)","journal-title":"Neurology"},{"key":"25_CR8","doi-asserted-by":"publisher","first-page":"907171","DOI":"10.1155\/2014\/907171","volume":"2014","author":"F Chiacchio","year":"2014","unstructured":"Chiacchio, F., Pennisi, M., Russo, G., Motta, S., Pappalardo, F.: Agent-based modeling of the immune system: NetLogo, a promising framework. BioMed Res. Int. 2014, 907171 (2014)","journal-title":"BioMed Res. Int."},{"issue":"Suppl 6","key":"25_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-019-3181-y","volume":"20","author":"MK Chimeh","year":"2019","unstructured":"Chimeh, M.K., Richmond, P., Heywood, P., Pennisi, M., Pappalardo, F.: Parallelisation strategies for agent based simulation of immune systems. BMC Bioinform. 20(Suppl 6), 1\u201314 (2019). https:\/\/doi.org\/10.1186\/s12859-019-3181-y","journal-title":"BMC Bioinform."},{"key":"25_CR10","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","volume":"381","author":"R Gold","year":"2013","unstructured":"Gold, R., et al.: Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 381, 2167\u201375 (2013)","journal-title":"Lancet"},{"issue":"2","key":"25_CR11","doi-asserted-by":"publisher","first-page":"e4565","DOI":"10.1371\/journal.pone.0004565","volume":"4","author":"D Godin","year":"2009","unstructured":"Godin, D.: The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One 4(2), e4565 (2009)","journal-title":"PLoS One"},{"issue":"9","key":"25_CR12","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.4049\/jimmunol.179.9.6273","volume":"179","author":"S Gorman","year":"2007","unstructured":"Gorman, S., et al.: Topically applied 1,25-Dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J. Immunol. 179(9), 6273\u20136283 (2007)","journal-title":"J. Immunol."},{"issue":"4","key":"25_CR13","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.4049\/jimmunol.167.4.1945","volume":"167","author":"S Gregori","year":"2001","unstructured":"Gregori, S., Casorati, M., Amuchastegui, S., Smiroldo, S., Davalli, A., Adorini, L.: Regulatory T cells induced by 1 alpha, 25-Dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 167(4), 1945\u20131953 (2001)","journal-title":"J. Immunol."},{"key":"25_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jneuroim.2016.09.001","volume":"299","author":"JA Lim","year":"2016","unstructured":"Lim, J.A., et al.: New feasible treatment for refractory autoimmune encephalitis: low-dose interleukin-2. J. Neuroimmunol. 299, 107\u2013111 (2016)","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"25_CR15","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1212\/NXI.0000000000000481","volume":"5","author":"F Luessi","year":"2018","unstructured":"Luessi, F., Engel, S., Spreer, A., Bittner, S., Zipp, F.: GFAP$$\\alpha $$ IgG-associated encephalitis upon daclizumab treatment of MS. Neurol. Neuroimmunol. Neuroinflamm. 5(5), e481 (2018)","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"25_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev.iy.10.040192.001101","volume":"10","author":"R Martin","year":"2003","unstructured":"Martin, R., McFarland, H.F., McFarlin, D.E.: Immunological aspects of demyelinating diseases. Ann. Rev. Immunol. 10, 153\u2013187 (2003)","journal-title":"Ann. Rev. Immunol."},{"key":"25_CR17","doi-asserted-by":"crossref","unstructured":"Pappalardo, F., Pennisi, M., Rajput, A.M., Chiacchio, F., Motta, S.: Relapsing-remitting multiple scleroris and the role of vitamin D : an agent based model. In: ACM-BCB, pp. 744\u2013748 (2014)","DOI":"10.1145\/2649387.2660844"},{"issue":"10","key":"25_CR18","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1182\/blood-2005-05-2044","volume":"106","author":"G Penna","year":"2005","unstructured":"Penna, G., et al.: Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory t cells by 1,25-dihydroxyvitamin D3. Blood 106(10), 3490\u20133497 (2005)","journal-title":"Blood"},{"issue":"Suppl 16","key":"25_CR19","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1186\/1471-2105-14-S16-S9","volume":"14","author":"M Pennisi","year":"2013","unstructured":"Pennisi, M., Rajput, A.M., Toldo, L., Pappalardo, F.: Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis. BMC Bioinf. 14(Suppl 16), S9 (2013)","journal-title":"BMC Bioinf."},{"key":"25_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jim.2015.08.014","volume":"427","author":"M Pennisi","year":"2015","unstructured":"Pennisi, M., Russo, G., Motta, S., Pappalardo, F.: Agent based modeling of the effects of potential treatments over the blood-brain barrier in multiple sclerosis. J. Immunol. Methods 427, 6\u201312 (2015)","journal-title":"J. Immunol. Methods"},{"issue":"4","key":"25_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1001\/jama.293.4.463","volume":"293","author":"A Ponsonby","year":"2005","unstructured":"Ponsonby, A., et al.: Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA 293(4), 463\u2013469 (2005)","journal-title":"JAMA"},{"key":"25_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","volume":"23","author":"M Sospedra","year":"2005","unstructured":"Sospedra, M., Martin, R.: Immunology of multiple sclerosis. Annu. Rev. Immunol. 23, 683\u2013747 (2005)","journal-title":"Annu. Rev. Immunol."},{"key":"25_CR23","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1212\/01.WNL.0000130496.51156.D7","volume":"62","author":"P Sundstr\u00f6m","year":"2004","unstructured":"Sundstr\u00f6m, P., et al.: An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 62, 2277\u20132282 (2004)","journal-title":"Neurology"},{"issue":"1","key":"25_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1752-0509-5-114","volume":"5","author":"N V\u00e9lez de Mendiz\u00e1bal","year":"2011","unstructured":"V\u00e9lez de Mendiz\u00e1bal, N., et al.: Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in multiple sclerosis. BMC Syst. Biol. 5(1), 1\u201315 (2011)","journal-title":"BMC Syst. Biol."},{"key":"25_CR25","unstructured":"Wilensky, U.: NetLogo, Center for connected learning and computer-based modeling, Northwestern University, Evanston, IL (1999). http:\/\/ccl.northwestern.edu\/netlogo\/"},{"issue":"5","key":"25_CR26","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nm.2365","volume":"17","author":"SC Wuest","year":"2011","unstructured":"Wuest, S.C., et al.: A role for interleukin-2 transpresentation in dendritic cellmediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 17(5), 604\u2013609 (2011)","journal-title":"Nat. Med."}],"container-title":["Lecture Notes in Computer Science","Computational Intelligence Methods for Bioinformatics and Biostatistics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-63061-4_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T21:28:13Z","timestamp":1697318893000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-63061-4_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030630607","9783030630614"],"references-count":26,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-63061-4_25","relation":{},"ISSN":["0302-9743","1611-3349"],"issn-type":[{"value":"0302-9743","type":"print"},{"value":"1611-3349","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"10 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"CIBB","order":1,"name":"conference_acronym","label":"Conference Acronym","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"International Meeting on Computational Intelligence Methods for Bioinformatics and Biostatistics","order":2,"name":"conference_name","label":"Conference Name","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Bergamo","order":3,"name":"conference_city","label":"Conference City","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Italy","order":4,"name":"conference_country","label":"Conference Country","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"2019","order":5,"name":"conference_year","label":"Conference Year","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"4 September 2019","order":7,"name":"conference_start_date","label":"Conference Start Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"6 September 2019","order":8,"name":"conference_end_date","label":"Conference End Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"16","order":9,"name":"conference_number","label":"Conference Number","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"cibb2019","order":10,"name":"conference_id","label":"Conference ID","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"https:\/\/dinamico2.unibg.it\/cazzaniga\/cibb2019\/index.html","order":11,"name":"conference_url","label":"Conference URL","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Single-blind","order":1,"name":"type","label":"Type","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"EasyChair","order":2,"name":"conference_management_system","label":"Conference Management System","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"55","order":3,"name":"number_of_submissions_sent_for_review","label":"Number of Submissions Sent for Review","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"28","order":4,"name":"number_of_full_papers_accepted","label":"Number of Full Papers Accepted","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"0","order":5,"name":"number_of_short_papers_accepted","label":"Number of Short Papers Accepted","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"51% - The value is computed by the equation \"Number of Full Papers Accepted \/ Number of Submissions Sent for Review * 100\" and then rounded to a whole number.","order":6,"name":"acceptance_rate_of_full_papers","label":"Acceptance Rate of Full Papers","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"2,3","order":7,"name":"average_number_of_reviews_per_paper","label":"Average Number of Reviews per Paper","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"2,4","order":8,"name":"average_number_of_papers_per_reviewer","label":"Average Number of Papers per Reviewer","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"Yes","order":9,"name":"external_reviewers_involved","label":"External Reviewers Involved","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}}]}}